For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00United Kingdom
+44 (0)20 36 36 94 00France
+33 (0)18 375 62 73We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United Kingdom
+44 (0)20 36 36 94 00United States of America
+1 (0)21 237 601 34Joint Bookrunner
Kempen & Co is pleased to announce that it acted as Joint Bookrunner in Q-linea’s SEK 301m Capital Increase
Q-linea is a diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. The company has signed a global partnership (excl. Sweden) with Thermo Fisher for the commercialisation of ASTar®. ASTar® recently achieved CE-IVD approval allowing Q-linea and Thermo Fisher to start commercialisation in Europe. In addition, the Q-linea recently initiated a 510(k) US clinical study for ASTar® with the goal of submitting a 510(k) application to the FDA during 2021.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: